Corrigendum: Safety of Semaglutide

Front Endocrinol (Lausanne). 2021 Nov 10:12:786732. doi: 10.3389/fendo.2021.786732. eCollection 2021.

Abstract

[This corrects the article DOI: 10.3389/fendo.2021.645563.].

Keywords: glucagon-like peptide-1 receptor agonist (GLP-1RA); oral; safety; semaglutide; subcutaneous; type 2 diabetes.

Publication types

  • Published Erratum